Reviewer’s report

Title: Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following Rituximab treatment in renal allograft.

Version: 1 Date: 10 Oct 2018

Reviewer: Shigeo Hara

Reviewer’s report:

Authors have reported the case of recurrent PGNMID that was treated with rituximab therapy in combination with plasapheresis, IVIG and steroid pulse. Serial renal histology showed histological changes from endocapillary proliferative to mesangial proliferative pattern. IF studies revealed IgG3-κ limited immune complex which was negative on second biopsy. EM studies showed disappearance of immune deposits. Subsequent development of chronic ABMR led to the renal graft failure.

This is a unique case of recurrent PGNMID that is highlighted with amenable effect, both histologically and clinically, of anti-B-cell treatment upon recurrent PGNMID. Changes of light microscopic findings to mesangial cell proliferative glomerulonephritis in 2nd biopsy is reminiscent of resolving phase post-infectious glomerulonephritis. Following are some comments that potentially strengthen the scientific value of this manuscript.

1. There seems to be slow response in urine protein and serum creatinine levels following the treatment despite histological improvement. Rather, peak proteinuria and renal dysfunction came to several months after the anti-B-cell treatment. Please explain this discrepancy.

2. Glomerular C4d staining in 1st and 2nd biopsy will provide further insight into the treatment response.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

'I declare that I have no competing interests.'

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.
I agree to the open peer review policy of the journal.